The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; L'Oreal; Lilly; Novartis; Pfizer; Sanofi; Teva Innovation Canada
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis; Pfizer; Sanofi
 
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Lilly; MSD Oncology; Nektar; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Tesaro; Teva
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Hexal; Lilly; Nektar; Roche; Seagen
Research Funding - Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer; Roche
Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.
 
Hans-Christian Kolberg
Stock and Other Ownership Interests - Phaon Scientific; Theraclion
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Genomic Health; MSD Oncology; Novartis; Onkowissen; Pfizer; Roche; SurgVision; Theraclion; Theramex
Consulting or Advisory Role - Amgen; SurgVision
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro
 
Özlem Yüksel
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst)
 
Sara Brucker
Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Olympus; Pfizer; Roche; Storz; Teva
Research Funding - Genomic Health (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Novartis; Olympus; Pfizer; Roche; Storz; Teva
 
Hans Tesch
Honoraria - Amgen; AstraZeneca; Eisai; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Vifor Pharma
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Eisai Europe; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Vifor Pharma
 
Diethelm Wallwiener
Consulting or Advisory Role - Consal
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Sanofi (Inst)
 
Lothar Haeberle
No Relationships to Disclose
 
Markus Wallwiener
Honoraria - AstraZeneca; Celgene; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Peyman Hadji
No Relationships to Disclose
 
Tanja N. Fehm
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Wolfgang Janni
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; Seagen
Research Funding - Amgen (Inst); Janssen Diagnostics; Lilly (Inst); Menarini Silicon Biosystems; Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Diana Lüftner
No Relationships to Disclose
 
Michael P Lux
Honoraria - AstraZeneca; Eisai; Genomic Health; Hexal; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Eisai; Genomic Health; Grunenthal; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche Pharma AG
Speakers' Bureau - AstraZeneca; Eisai Germany; Exact Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG
Research Funding - Discovering Hands (Inst); German Breast Group (Inst); Grunenthal (Inst); MSD Oncology (Inst); PRAEGNANT Network (Inst); Roche (Inst); SamanTree Medical (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche Pharma AG
Other Relationship - Medac
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Pfizer
 
Johannes Ettl
Honoraria - AstraZeneca; Celgene; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Tesaro; Teva
Consulting or Advisory Role - Daiichi Sankyo; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Tesaro
Speakers' Bureau - AstraZeneca; Celgene; Lilly; Pfizer; Roche; Teva
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Celgene; Lilly; Novartis; Pfizer; Teva
Other Relationship - Tesaro
 
Andreas D. Hartkopf
Honoraria - Agendia; Amgen; AstraZeneca; Daiichi Sankyo; Genomic Health; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
 
Volkmar Müller
No Relationships to Disclose
 
Florin-Andrei Taran
No Relationships to Disclose
 
Erik Belleville
Consulting or Advisory Role - Hexal (Inst); Novartis (Inst)
Research Funding - AstraZeneca (Inst); Hexal (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - onkowissen (Inst)
 
Alexander Hein
No Relationships to Disclose
 
Andreas Schneeweiss
Honoraria - AstraZeneca; Celgene; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Tesaro
Research Funding - Abbvie; Celgene (Inst); Molecular Partners; Roche Pharma AG (Inst)
Expert Testimony - AstraZeneca; Roche
Travel, Accommodations, Expenses - Celgene; Roche